Strategies for enhancing vaccine-induced CTL antitumor immune responses

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Yong, Xin ^a   Xiao, Yü Feng ^a   Luo, Gang ^a   He, Bin ^a   Lü, Mu Han ^a   Hu, Chang Jiang ^a   Guo, Hong ^a   Yang, Shi Ming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CANCER VACCINE; CETUXIMAB; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; PEPTIDE VACCINE; SUNITINIB; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BASAL CELL CARCINOMA; BREAST CANCER; CELL DIFFERENTIATION; CELL GROWTH; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MELANOMA; METASTASIS; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PHAGOCYTOSIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; NEOPLASM;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84871837384     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/605045     Document Type: Review

References (84)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Dougan M., Dranoff G., Immune therapy for cancer. Annual Review of Immunology 2009 27 83 117 2-s2.0-67650744372 10.1146/annurev.immunol.021908. 132544
3. Porter D. L., Levine B. L., Kalos M., Bagg A., June C. H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine 2011 365 8 725 733
4. Lewis Phillips G. D., Li G., Dugger D. L., Crocker L. M., Parsons K. L., Mai E., Blättler W. A., Lambert J. M., Chari R. V. J., Lutz R. J., Wong W. L. T., Jacobson F. S., Koeppen H., Schwall R. H., Kenkare-Mitra S. R., Spencer S. D., Sliwkowski M. X., Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Research 2008 68 22 9280 9290 2-s2.0-56449129810 10.1158/0008-5472.CAN-08-1776
5. Madan R. A., Gulley J. L., Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Review of Vaccines 2011 10 2 141 150 2-s2.0-79951871014 10.1586/erv.10.173
6. Matteo V., Chiara I., Ngar-Yee H., Strategies for cancer vaccine development. Journal of Biomedicine and Biotechnology 2010 2010 13 596432
7. Mellman I., Steinman R. M., Dendritic cells: specialized and regulated antigen processing machines. Cell 2001 106 3 255 258 2-s2.0-0035838984 10.1016/S0092-8674(01)00449-4 (Pubitemid 32772607)
8. Palucka K., Banchereau J., Mellman I., Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010 33 4 464 478 2-s2.0-77958454596 10.1016/j.immuni.2010.10.007
9. Zitvogel L., Kroemer G., Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. Journal of Clinical Investigation 2009 119 8 2127 2130 2-s2.0-68849086119 10.1172/JCI39991
10. Kenter G. G., Welters M. J. P., Valentijn A. R. P. M., Lowik M. J. G., Berends-van Der Meer D. M. A., Vloon A. P. G., Essahsah F., Fathers L. M., Offringa R., Drijfhout J. W., Wafelman A. R., Oostendorp J., Fleuren G. J., Van Der Burg S. H., Melief C. J. M., Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. The New England Journal of Medicine 2009 361 19 1838 1847 2-s2.0-70350772293 10.1056/NEJMoa0810097
11. Darrasse-Jèze G., Deroubaix S., Mouquet H., Victora G. D., Eisenreich T., Yao K. H., Masilamani R. F., Dustin M. L., Rudensky A., Liu K., Nussenzweig M. C., Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. Journal of Experimental Medicine 2009 206 9 1853 1862 2-s2.0-69549103141 10.1084/jem.20090746
12. Jiang A., Bloom O., Ono S., Cui W., Unternaehrer J., Jiang S., Whitney J. A., Connolly J., Banchereau J., Mellman I., Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 2007 27 4 610 624 2-s2.0-35348968837 10.1016/j.immuni.2007.08.015 (Pubitemid 47615505)
13. Steinman R. M., Hawiger D., Nussenzweig M. C., Tolerogenic dendritic cells. Annual Review of Immunology 2003 21 685 711 2-s2.0-0042971652 10.1146/annurev.immunol.21.120601.141040 (Pubitemid 37174545)
14. Matthew V., Glenn D., Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer 2012 12 4 237 251
15. Nefedova Y., Nagaraj S., Rosenbauer A., Muro-Cacho C., Sebti S. M., Gabrilovich D. I., Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Research 2005 65 20 9525 9535 2-s2.0-27144538568 10.1158/0008-5472.CAN-05-0529 (Pubitemid 41508023)
16. Nefedova Y., Cheng P., Gilkes D., Blaskovich M., Beg A. A., Sebti S. M., Gabrilovich D. I., Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. Journal of Immunology 2005 175 7 4338 4346 2-s2.0-25444444988 (Pubitemid 41361968)
17. Korman A. J., Peggs K. S., Allison J. P., Checkpoint blockade in cancer immunotherapy. Advances in Immunology 2006 90 297 339 2-s2.0-33646794392 10.1016/S0065-2776(06)90008-X (Pubitemid 43765802)
18. Farsaci B., Higgins J. P., Hodge J. W., Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. International Journal of Cancer 2011 130 8 1948 1959 2-s2.0-79961153024 10.1002/ijc.26219
19. Ko J. S., Zea A. H., Rini B. I., Ireland J. L., Elson P., Cohen P., Golshayan A., Rayman P. A., Wood L., Garcia J., Dreicer R., Bukowski R., Finke J. H., Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clinical Cancer Research 2009 15 6 2148 2157 2-s2.0-63549105681 10.1158/1078-0432.CCR-08-1332
20. Schreiber R. D., Old L. J., Smyth M. J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011 331 6024 1565 1570 2-s2.0-79953151458 10.1126/science.1203486
21. Palucka K., Banchereau J., Mellman I., Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010 33 4 464 478 2-s2.0-77958454596 10.1016/j.immuni.2010.10.007
22. Zitvogel L., Kroemer G., Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. Journal of Clinical Investigation 2009 119 8 2127 2130 2-s2.0-68849086119 10.1172/JCI39991
23. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
24. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011 364 26 2517 2526 2-s2.0-79959772576 10.1056/NEJMoa1104621
25. Sharma P., Wagner K., Wolchok J. D., Allison J. P., Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews Cancer 2011 11 11 805 812
26. Palena C., Abrams S. I., Schlom J., Hodge J. W., Cancer vaccines: preclinical studies and novel strategies. Advances in Cancer Research 2006 95 115 145 2-s2.0-33745988889 10.1016/S0065-230X(06)95004-0 (Pubitemid 44066525)
27. Cerundolo V., Hermans I. F., Salio M., Dendritic cells: a journey from laboratory to clinic. Nature Immunology 2004 5 1 7 10 2-s2.0-0345865089 10.1038/ni0104-7 (Pubitemid 38081459)
28. Lesterhuis W. J., de Vries I. J. M., Adema G. J., Punt C. J. A., Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Annals of Oncology 2004 15 4 iv145 iv151 2-s2.0-9744244917 10.1093/annonc/mdh919 (Pubitemid 39585327)
29. Tong X. M., Zheng S. E., Bader A., Yao H. P., Wu N. P., Altmeyer P., Brockmeyer N. H., Jin J., Construction of expression vector of HTERT- HIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT. European Journal of Medical Research 2008 13 1 7 14 2-s2.0-38949185310 (Pubitemid 351227757)
30. Trombetta E. S., Mellman I., Cell biology of antigen processing in vitro and in vivo. Annual Review of Immunology 2005 23 975 1028 2-s2.0-17644370329 10.1146/annurev.immunol.22.012703.104538 (Pubitemid 40563191)
31. Correale P., Botta C., Cusi M. G., Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. International Journal of Cancer 2012 130 7 1577 1589
32. Wolpoe M. E., Lutz E. R., Ercolini A. M., Murata S., Ivie S. E., Garrett E. S., Emens L. A., Jaffee E. M., Reilly R. T., HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. Journal of Immunology 2003 171 4 2161 2169 2-s2.0-0043136619 (Pubitemid 36966500)
33. Boruchov A. M., Heller G., Veri M. C., Bonvini E., Ravetch J. V., Young J. W., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. Journal of Clinical Investigation 2005 115 10 2914 2923 2-s2.0-26444577543 10.1172/JCI24772 (Pubitemid 41434419)
34. Kim P. S., Armstrong T. D., Song H., Wolpoe M. E., Weiss V., Manning E. A., Huang L. Q., Murata S., Sgouros G., Emens L. A., Reilly R. T., Jaffee E. M., Antibody association with HER-2/neu-targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs. Journal of Clinical Investigation 2008 118 5 1700 1711 2-s2.0-43049144967 10.1172/JCI34333 (Pubitemid 351632374)
35. Disis M. L., Wallace D. R., Gooley T. A., Dang Y., Slota M., Lu H., Coveler A. L., Childs J. S., Higgins D. M., Fintak P. A., Dela Rosa C., Tietje K., Link J., Waisman J., Salazar L. G., Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. Journal of Clinical Oncology 2009 27 28 4685 4692 2-s2.0-70350435441 10.1200/JCO.2008.20.6789
36. Rosenberg S. A., Yang J. C., Restifo N. P., Cancer immunotherapy: moving beyond current vaccines. Nature Medicine 2004 10 9 909 915 2-s2.0-4644324025 10.1038/nm1100 (Pubitemid 39273730)
37. Mellman I., Coukos G., Dranoff G., Cancer immunotherapy comes of age. Nature 2011 480 7378 480 489
38. Carfí M., Bowe G., Ferrario D., Pieters R., Gribaldo L., Maintenance and characterization of lymphocytes in human long term bone marrow cultures to study immunotoxicity. Toxicology in Vitro 2010 24 5 1395 1403 2-s2.0-77953619305 10.1016/j.tiv.2010.04.014
39. Klapper J. A., Thomasian A. A., Smith D. M., Gorgas G. C., Wunderlich J. R., Smith F. O., Hampson B. S., Rosenberg S. A., Dudley M. E., Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. Journal of Immunological Methods 2009 345 1-2 90 99 2-s2.0-65749108349 10.1016/j.jim.2009.04.009
40. Iwasaki A., Medzhitov R., Toll-like receptor control of the adaptive immune responses. Nature Immunology 2004 5 10 987 995 2-s2.0-5444262511 10.1038/ni1112 (Pubitemid 41057715)
41. Chang Y. C., Madkan V., Cook-Norris R., Sra K., Tyring S., Current and potential uses of imiquimod. Southern Medical Journal 2005 98 9 914 920 2-s2.0-25844505692 10.1097/01.SMJ.0000176712.01491.98 (Pubitemid 41396088)
42. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. Journal of Clinical Investigation 2005 115 3 739 746 2-s2.0-14644390867 10.1172/JCI200523373 (Pubitemid 40322250)
43. Krieg A. M., Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides. Current Oncology Reports 2004 6 2 88 95 2-s2.0-2342558523 (Pubitemid 38898835)
44. Krieg A. M., Therapeutic potential of toll-like receptor 9 activation. Nature Reviews Drug Discovery 2006 5 6 471 484 2-s2.0-33745946911 10.1038/nrd2059 (Pubitemid 44136959)
45. Rabinovich G. A., Gabrilovich D., Sotomayor E. M., Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology 2007 25 267 296 2-s2.0-33947259319 10.1146/annurev.immunol.25.022106.141609 (Pubitemid 46697910)
46. Bhowmick N. A., Neilson E. G., Moses H. L., Stromal fibroblasts in cancer initiation and progression. Nature 2004 432 7015 332 337 2-s2.0-9244227134 10.1038/nature03096 (Pubitemid 39551661)
47. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004 10 9 942 949 2-s2.0-4644237613 10.1038/nm1093 (Pubitemid 39273735)
48. Kono K., Kawaida H., Takahashi A., Sugai H., Mimura K., Miyagawa N., Omata H., Fujii H., CD4(+) CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunology, Immunotherapy 2006 55 9 1064 1071 2-s2.0-33744457276 10.1007/s00262-005-0092-8 (Pubitemid 43800721)
49. Ozao-Choy J., Ge M., Kao J., Wang G. X., Meseck M., Sung M., Schwartz M., Divino C. M., Pan P. Y., Chen S. H., The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Research 2009 69 6 2514 2522 2-s2.0-65549141834 10.1158/0008-5472.CAN-08-4709
50. Alfaro C., Suarez N., Gonzalez A., Solano S., Erro L., Dubrot J., Palazon A., Hervas-Stubbs S., Gurpide A., Lopez-Picazo J. M., Grande-Pulido E., Melero I., Perez-Gracia J. L., Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. British Journal of Cancer 2009 100 7 1111 1119 2-s2.0-63949087054 10.1038/sj.bjc.6604965
51. Yang D. H., Park J. S., Jin C. J., Kang H. K., Nam J. H., Rhee J. H., Kim Y. K., Chung S. Y., Choi S. J. N., Kim H. J., Chung I. J., Lee J. J., The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leukemia Research 2009 33 5 665 670 2-s2.0-61649125595 10.1016/j.leukres.2008.09.006
52. + T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2007 104 9 3360 3365 2-s2.0-33847611968 10.1073/pnas.0611533104 (Pubitemid 46364164)
53. Keir M. E., Butte M. J., Freeman G. J., Sharpe A. H., PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology 2008 26 677 704 2-s2.0-42649125225 10.1146/annurev.immunol.26.021607.090331 (Pubitemid 351600389)
54. Chambers C. A., Kuhns M. S., Egen J. G., Allison J. P., CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annual Review of Immunology 2001 19 565 594 2-s2.0-0035056017 10.1146/annurev.immunol.19.1.565 (Pubitemid 32368046)
55. Workman C. J., Vignali D. A. A., Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). Journal of Immunology 2005 174 2 688 695 2-s2.0-11844269957 (Pubitemid 40094261)
56. Huang C. T., Workman C. J., Files D., Role of LAG-3in regulatoryT cells. Immunity 2004 21 4 503 513
57. Facciabene A., Peng X., Hagemann I. S., Balint K., Barchetti A., Wang L. P., Gimotty P. A., Gilks C. B., Lal P., Zhang L., Coukos G., Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells. Nature 2011 475 7355 226 230 2-s2.0-79960393113 10.1038/nature10169
58. Kantoff P. W., Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine 2010 363 5 411 422 2-s2.0-77955066199 10.1056/NEJMoa1001294
59. Balachandran V. P., Cavnar M. J., Zeng S., Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine 2011 17 9 1094 1100
60. + regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. Journal of Immunology 2008 181 10 6955 6963 2-s2.0-58149187113
61. Bose A., Taylor J. L., Alber S., Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. International Journal of Cancer 2011 129 9 2158 2170
62. Tivol E. A., Borriello F., Schweitzer A. N., Lynch W. P., Bluestone J. A., Sharpe A. H., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995 3 5 541 547 2-s2.0-0028867420
63. + regulatory T cell function. Science 2008 322 5899 271 275 2-s2.0-53749094183 10.1126/science.1160062
64. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
65. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011 364 26 2517 2526 2-s2.0-79959772576 10.1056/NEJMoa1104621
66. Kagi D., Vignaux F., Ledermann B., Burki K., Depraetere V., Nagata S., Hengartner H., Golstein P., Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994 265 5171 528 530 2-s2.0-0028110928 (Pubitemid 24264998)
67. Kojima H., Shinohara N., Hanaoka S., Someya-Shirota Y., Takagaki Y., Ohno H., Saito T., Katayama T., Yagita H., Okumura K., Shinkai Y., Alt F. W., Matsuzawa A., Yonehara S., Takayama H., Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994 1 5 357 364 2-s2.0-0028486130
68. Stinchcombe J. C., Bossi G., Booth S., Griffiths G. M., The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 2001 15 5 751 761 2-s2.0-0035655587 10.1016/S1074-7613(01)00234-5 (Pubitemid 34008503)
69. Stinchcombe J. C., Griffiths G. M., Secretory mechanisms in cell-mediated cytotoxicity. Annual Review of Cell and Developmental Biology 2007 23 495 517 2-s2.0-38449096740 10.1146/annurev.cellbio.23.090506.123521
70. Cullen S. P., Martin S. J., Mechanisms of granule-dependent killing. Cell Death and Differentiation 2008 15 2 251 262 2-s2.0-38049103314 10.1038/sj.cdd.4402244
71. Pardo J., Wallich R., Martin P., Urban C., Rongvaux A., Flavell R. A., Müllbacher A., Borner C., Simon M. M., Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs. Cell Death and Differentiation 2008 15 3 567 579 2-s2.0-39449096047 10.1038/sj.cdd.4402289 (Pubitemid 351267307)
72. Hassin D., Garber O. G., Meiraz A., Schiffenbauer Y. S., Berke G., Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable. Immunology 2011 133 2 190 196 2-s2.0-79954991695 10.1111/j.1365-2567.2011.03426.x
73. Kischkel F. C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P. H., Peter M. E., Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO Journal 1995 14 22 5579 5588 2-s2.0-0028883850
74. Kang T. B., Oh G. S., Scandella E., Bolinger B., Ludewig B., Kovalenko A., Wallach D., Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic functions in bacterial artificial chromosome-transgenic mice. Journal of Immunology 2008 181 4 2522 2532 2-s2.0-52149095957
75. Strasser A., Jost P. J., Nagata S., The many roles of FAS receptor signaling in the immune system. Immunity 2009 30 2 180 192 2-s2.0-60149085396 10.1016/j.immuni.2009.01.001
76. Hamaï A., Benlalam H., Meslin F., Hasmim M., Carré T., Akalay I., Janji B., Berchem G., Noman M. Z., Chouaib S., Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 2010 75 1 1 8 2-s2.0-72649104033 10.1111/j.1399-0039.2009.01401.x
77. Marincola F. M., Jaffee E. M., Hickljn D. J., Ferrone S., Escape of human solid tumors from t-cell recognition: molecular mechanisms and functional significance. Advances in Immunology 2000 74 181 273 2-s2.0-0033991158
78. Seeger J. M., Schmidt P., Brinkmann K., Hombach A. A., Coutelle O., Zigrino P., Wagner-Stippich D., Mauch C., Abken H., Krönke M., Kashkar H., The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Research 2010 70 5 1825 1834 2-s2.0-77950205394 10.1158/0008-5472.CAN-09-3175
79. + T-cell-mediated antitumor immunity induced by DNA vaccination. Journal of Molecular Medicine 2008 86 8 899 908 2-s2.0-48149087775 10.1007/s00109-008-0370-y
80. Chen L., Willis S. N., Wei A., Smith B. J., Fletcher J. I., Hinds M. G., Colman P. M., Day C. L., Adams J. M., Huang D. C. S., Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 2005 17 3 393 403 2-s2.0-19944432123 10.1016/j.molcel.2004.12.030 (Pubitemid 40193310)
81. Hallett W. H. D., Ames E., Motarjemi M., Barao I., Shanker A., Tamang D. L., Sayers T. J., Hudig D., Murphy W. J., Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. Journal of Immunology 2008 180 1 163 170 2-s2.0-40449100492
82. Shi J., Tricot G. J., Garg T. K., Malaviarachchi P. A., Szmania S. M., Kellum R. E., Storrie B., Mulder A., Shaughnessy J. D., Barlogie B., Van Rhee F., Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 2008 111 3 1309 1317 2-s2.0-38949113714 10.1182/blood-2007-03-078535 (Pubitemid 351213417)
83. Hähnel P. S., Thaler S., Antunes E., Huber C., Theobald M., Schuler M., Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Research 2008 68 10 3899 3906 2-s2.0-45549086241 10.1158/0008-5472.CAN-07-6286
84. Noh K. H., Kang T. H., Kim J. H., Pai S. I., Lin K. Y., Hung C. F., Wu T. C., Kim T. W., Activation of Akt as a mechanism for tumor immune evasion. Molecular Therapy 2009 17 3 439 447 2-s2.0-61649110680 10.1038/mt.2008.255